drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Off-the-shelf, allogeneic, lentiviral-engineered double-negative T cells (DNTs) expressing an anti-CD19 chimeric antigen receptor (CAR) to target and kill CD19-positive malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Off-the-shelf allogeneic double-negative T cells engineered with an anti-CD19 chimeric antigen receptor bind CD19 on malignant B cells; CAR signaling activates the DNTs to exert cytotoxicity and eliminate CD19-positive tumor cells.
drug_name
RJMty19
nct_id_drug_ref
NCT06314828